May 21 (Reuters) - The U.S Food and Drug Administration has approved Dova Pharmaceuticals Inc's drug to treat thrombocytopenia, or low blood platelet count, in patients with chronic liver disease, the agency said on Monday.
FDA approves Dova Pharma's blood disorder drug
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться